• About us
• Contact

Advertisement

Organisation › Details

BioVersys AG

The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology it will be possible to restore the efficacy of established antibiotics. BioVersys addresses the high unmet medical need for new treatments of life-threatening bacterial infections that emerged in recent years due to antibiotic resistance. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is on Nosocomial Infections (hospital infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille BioVersys aims to develop an effective treatment against *

 

	Start	2008-09-19 splitoff
	Predecessor	ETH Zürich, Dept. of Biosystems Science and Engineering (D-BSSE, Basel)
	Industry	antibiotic
	Person	Gitzinger, Marc (BioVersys 2008– CEO + Co-founder)
	Person 2	Tigges, Marcel (BioVersys 2008– CSO + Co-founder)
	Region	Basel BS
	Country	Switzerland
	Street	60c Hochbergerstr. Technologiepark Basel, 3rd Floor
	City	4057 Basel BS
	Tel	+41-61-387-3289
		Address record changed: 2020-12-02
Basic data	Employees	A: 1 to 10 (2011-04-28)
		* Document for »About Section«:
		Record changed: 2024-05-07

Advertisement

More documents for BioVersys AG

• [1] BioVersys AG. (5/7/24). "Press Release: BioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million". Basel....
• [2] BioVersys AG. (1/5/23). "Press Release: BioVersys Extends Its Series C Round to CHF 32.6 Million with investment from the AMR Action Fund". Basel....
• [3] BioVersys AG. (6/8/22). "Press Release: BioVersys AG Announces Successful First Closing of CHF 24.2 Million Series C Financing to Develop Clinical Pipeline of Novel AMR Therapies". Basel....
• [4] BioVersys AG. (6/1/21). "Press Release: BioVersys Receives a Second CARB-X Award of up to US$ 15.34 Milllion for BV300". Basel....
• [5] BioVersys AG. (5/18/21). "Press Release: Martin Bott Appointed CFO of BioVersys". Basel....
• [6] BioVersys AG. (4/14/21). "Press Release: BioVersys Receives €20 Million in EU financing to Support Development of New Antibiotics"....
• [7] BioVersys AG. (9/1/20). "Press Release: BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.